Northwest Biotherapeutics: All Is Not Well With This One
…
0,261€
3,57%
Echtzeit-Aktienkurs Northwest Biotherapeutics Inc.
Bid:
Ask:
Nachrichten zur Northwest Biotherapeutics Inc. Aktie
1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors
YONGIN, South Korea, December 14, 2023 – 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel…